J&J inks 2nd manufacturing deal to boost capacity for COVID-19 vaccine

J&J
Johnson & Johnson inked a deal with Emergent last week to boost capacity for its COVID-19 shot. (Johnson & Johnson)

Johnson & Johnson, one of a wave of companies racing to produce a vaccine for the novel coronavirus, aims to sign up a network of manufacturing partners to help boost capacity ahead of a potential FDA approval. Now, in its second sweeping production deal, J&J has paired up with Catalent to set the stage for the shot's debut. 

J&J signed an agreement Wednesday to ramp up capacity at Catalent's 875,000-square-foot Bloomington, Indiana facility, the partners said Wednesday. 

Catalent will hire an additional 300 workers at the plant starting in July with the goal of reaching 24/7 manufacturing schedules by January. 

Leveraging its "deep expertise" in sterile formulation at the Bloomington facility, Catalent brings experience in drug substance development and manufacturing, and drug product fill/finish to the deal, the company said. Catalent will also lean on its network of sterile drug facilities in Brussels and Anagni, Italy. 

The Catalent deal is J&J's second agreement in as many weeks to scale up manufacturing capacity for its COVID-19 shot candidate in anticipation of a future approval. 

RELATED: Johnson & Johnson sets stage for COVID-19 shot rollout with 'first in a series' manufacturing deal

Last week, J&J inked a deal with Emergent BioSolutions to ramp up production of the shot, which the drugmaker hopes to take into human trials in September..

As part of its Emergent deal, J&J will expand its own capacity for producing the vaccine candidate, and Emergent will begin using its "molecule-to-market" manufacturing to chip in later this year. Emergent will also reserve capacity to support a potential commercial rollout of J&J's shot beginning as early as 2021 should it nab an approval.

J&J has already earmarked its own Leiden, Netherlands, facility for clinical vaccine production and plans to begin producing the vaccine "at-risk" to support human trials.

J&J called the Emergent deal the "first in a series" to help boost its global scale ahead of the hoped-for approvals.

RELATED: A bull's-eye from 24 feet? COVID-19 vaccine timelines are overly hopeful, analyst says

Despite J&J's hopes that its vaccine could be ready to ship as early as next year, some market watchers think that timeline is too optimistic.

In a 25-page note earlier this week titled “Sober Up! 25 Reasons Not to Count on COVID Vaccine for Herd Immunity in 1-2 years,” SVB Leerink analyst Geoffrey Porges says it’ll take several years—not months—to develop a safe and effective vaccine and administer it to enough people for widespread protection.

“We view the current expectations for a vaccine in this timeframe as the equivalent of standing 24 feet (the usual distance is 8 feet) from a dartboard, with one dart in hand, and counting on a bullseye from one throw,” the analyst wrote. “It is theoretically possible, but highly unlikely, that such expectations are correct.”

J&J and its fellow vaccine-making hopefuls are hoping to prove the analysts wrong, counting on new technologies, quick scale-ups and cooperation from regulators to make the difference.

Suggested Articles

Bayer has withdrawn part of a proposed Roundup settlement after a judge questioned how it's handling potential future claims.

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

The CEOs for COVID-19 vaccine partners Pfizer and BioNTech are sounding confident in their program as they gear up for phase 3.